Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448877 | PMC |
| http://dx.doi.org/10.1016/j.ekir.2020.08.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of oral early antiviral therapies for mild-moderate COVID-19 in the outpatient's setting during Omicron era: a pharmacoeconomic analysis.
Eur J Med Res
December 2024
Infectious and Tropical Diseases Unit, Padua University Hospital, 35128, Padua, Italy.
Background: Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) decreased mortality and hospital admissions in high-risk patients with mild to moderate COVID-19. Nevertheless, there is a lack of data about the pharmacoeconomic impact of these antivirals in the Omicron era. We conducted a pharmacoeconomic analysis assessing the medical costs of the use of these antivirals compared to those occurred in people who refused the treatment.
View Article and Find Full Text PDFIntroduction: The study aimed to compare the outcomes of nirmatrelvir and ritonavir drug combination (Paxlovid) therapy in patients who received treatment within or after five days of COVID-19 confirmed in the elderly.
Methodology: This was a single-center, retrospective cohort study of older COVID-19 patients (≥ 60 years) admitted from April 7 to May 30, 2022. Patients were categorized into the EP group (starting Paxlovid within five days) and the LP group (starting Paxlovid after five days) following symptoms onset.
Adverse perinatal outcomes associated with different classes of antiretroviral drugs in pregnant women with HIV.
AIDS
February 2025
National Perinatal Epidemiology Unit, Infectious Disease Epidemiology Unit, Nuffield Department of Population Health.
Article Synopsis
- Women living with HIV (WLHIV) face higher risks of negative pregnancy outcomes compared to HIV-negative women, even when on antiretroviral therapy (ART).
- A systematic review and meta-analysis were conducted to evaluate the perinatal risks among WLHIV using different ART regimens (NNRTI, PI, and INSTI) versus HIV-negative women, analyzing 22 cohort studies involving over 191,000 women.
- Results showed that WLHIV on NNRTI-based ART had significantly increased risks for several adverse outcomes, such as preterm birth and low birthweight, highlighting the impact of ART types on pregnancy health.
Real-world effectiveness of early anti-SARS therapy in severely immunocompromised COVID-19 outpatients during the SARS-CoV-2 omicron variant era: a propensity score-adjusted retrospective cohort study.
J Antimicrob Chemother
December 2024
Unit of Infectious Diseases, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
Background: The effectiveness of the early treatment for antiviral agents in SARS-CoV-2 infection is closely related to patient comorbidities. Data on effectiveness in immunocompromised patients are limited, with reports involving highly heterogeneous and not well-defined populations. We aimed to assess the effectiveness of treatment in reducing hospitalizations in a real-world cohort of severely immunocompromised COVID-19 outpatients.
View Article and Find Full Text PDFThe effectiveness of nirmatrelvir/ritonavir regimen in hospitalized renal transplant patients with prolonged COVID-19 infection: a multicenter clinical experience.
Ren Fail
December 2024
Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Objectives: Effectiveness of nirmatrelvir/ritonavir (NR) in kidney transplant recipients (KTRs) infected COVID-19 for more than 5 days has not been evaluated.
Methods: In this multicenter retrospective study, 85 KTRs with COVID-19 were enrolled, including 50 moderate, 21 severe, and 14 critical patients.
Results: The median time from onset to starting NR treatment was 14 (IQR, 11-19) days.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!